Novavax reports its candidate SARS-CoV-2 vaccine has a high efficacy rate, though that rate dropped against the South African strain of the virus, according to the New York Times.
In Nature this week: genetic and proteomic data gives Alzheimer's disease development insights, whole-genome doubling could be targeted in cancer, and more.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.